MedTrace Logo

ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

NCT01583608 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 183

Last updated 2016-12-09

No results posted yet for this study

Summary

The registry aims to evaluate the safety, performance and efficacy of the Everolimus-eluting bioresorbable vascular scaffold (BVS) system in patients with de novo native coronary artery lesions in all-day clinical practice.

Conditions

Sponsors & Collaborators

  • Abbott Medical Devices

    collaborator INDUSTRY

  • Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.

    lead OTHER

Principal Investigators

  • Detlef G Mathey, MD · Medical Care Center Prof. Mathey, Prof. Schofer GmbH

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-03-31
Completion
2016-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01583608 on ClinicalTrials.gov